Recent studies have centered on the overlap of glucagon-like peptide-1|GIP|GCGR agonist therapies and dopaminergic communication. While GIP stimulators are increasingly employed for treating type 2 T2DM, their emerging consequences on motivation circuits, specifically governed by dopaminergic networks, are receiving substantial interest. This re… Read More